Shanghai and Seoul, November 29, 2019 - WuXi ATU Co., Ltd., (WuXi ATU) - a subsidiary of WuXi AppTec, and GeneMedicine - a South Korea-based gene therapy biotechnology company, have formed a strategic partnership for the development and manufacturing of oncolytic virus products. Under the terms of the collaboration, WuXi ATU will provide overall process development, manufacturing and Investigational New Drug (IND) filing services for GeneMedicine’s oncolytic virus products.
SHANGHAI, Nov. 18, 2019 - WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced its Lab Testing Division (LTD) has expanded the Suzhou safety assessment facility by increasing toxicology capacity by 80% to meet global customers’ preclinical testing needs and enable them to accelerate the development timelines and bring innovative medicines to patients faster.
SHANGHAI, Nov. 15, 2019 -- WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced that it received the 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award from Frost & Sullivan, a global business research and consulting firm. WuXi AppTec was awarded this honor for the third consecutive year.